Recent Posts
- ADX-097, potential AAV therapy, fares well in healthy volunteers October 16, 2024
- Long-term Nucala for EGPA eases disease activity, improves survival October 14, 2024
- Vasculitis Foundation launches new support group for young adults October 9, 2024
- AAV raises the risk of cardiovascular disease, review study finds October 7, 2024
- Phase 1 trial of CAR T-cell therapy will soon enroll AAV patients October 2, 2024
- CT scan damage may predict ANCA-associated vasculitis outcomes September 30, 2024
- Fasenra approval for EGPA in EU recommended by committee September 25, 2024
- Syndecan-1 levels may help ID AAV patients at risk of poor prognosis September 23, 2024
- FDA approves Fasenra for treating adults with rare AAV form EGPA September 19, 2024
- Rituximab may raise risks of adverse events in AAV: Study September 18, 2024